Veru Inc. (VERU): Price and Financial Metrics


Veru Inc. (VERU)

Today's Latest Price: $2.43 USD

0.00 (0.00%)

Updated Oct 22 4:00pm

Add VERU to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VERU Stock Summary

  • The ratio of debt to operating expenses for Veru Inc is higher than it is for about merely 20.14% of US stocks.
  • With a year-over-year growth in debt of -14.4%, Veru Inc's debt growth rate surpasses merely 17.59% of about US stocks.
  • Revenue growth over the past 12 months for Veru Inc comes in at 39.94%, a number that bests 87.82% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Veru Inc are RTRX, KPTI, SRNE, FBIO, and ATNX.
  • Visit VERU's SEC page to see the company's official filings. To visit the company's web site, go to www.verupharma.com.

VERU Stock Price Chart Interactive Chart >

Price chart for VERU

VERU Price/Volume Stats

Current price $2.43 52-week high $4.74
Prev. close $2.43 52-week low $1.85
Day low $2.42 Volume 129,200
Day high $2.47 Avg. volume 518,459
50-day MA $2.67 Dividend yield N/A
200-day MA $3.29 Market Cap 169.77M

Veru Inc. (VERU) Company Bio


Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.


VERU Latest News Stream


Event/Time News Detail
Loading, please wait...

VERU Latest Social Stream


Loading social stream, please wait...

View Full VERU Social Stream

Latest VERU News From Around the Web

Below are the latest news stories about Veru Inc that investors may wish to consider to help them evaluate VERU as an investment opportunity.

Veru enrolls in Phase 2 trial for an oral drug for metastatic prostate cancer

Veru ([[VERU]] +2.7%) has fully enrolled its Phase 2 clinical study of VERU-111, its novel, oral, alpha and beta tubulin targeting drug for metastatic castration and novel androgen receptor targeting agent resistant prostate cancer.The study enrolled a total of 40 men at 13 clinical sites in the U.S.Phase 2 clinical trial will...

Seeking Alpha | September 29, 2020

Veru (VERU) Presents At Morgan Stanley 18th Annual Global Healthcare Conference

The following slide deck was published by Veru Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 22, 2020

Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th

MIAMI, July 30, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 third quarter ended June 30, 2020, on Thursday, August 13, 2020 before the market opens.  Veru’s management will host a conference call that same day at 8 a.m. ET to review the Company’s performance and to answer questions.  The call will also be accessible via webcast. Event Details Interested parties may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call.  The call will also be available through a live, listen-only audio broadc...

Yahoo | July 30, 2020

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that the clinical results from its Phase 1b/2 study of VERU-111 have been accepted for oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to be held September 19-21, 2020. VERU-111 is a novel, oral, first-in-class, tubulin targeting agent that crosslinks and disrupts alpha and beta tubulin subunits of microtubules. VERU-111 is in clinical development to treat metastatic castration and novel androgen receptor targeting agent (enzalutamide or abiraterone) resistant prostate cancer, a growing unmet medical need in advanced prostate cancer...

Yahoo | July 27, 2020

Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

\--Pivotal Phase 3 Clinical Trial Expected to Initiate First Quarter Calendar Year 2021--MIAMI, July 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has received regulatory clarity from the U.S. Food and Drug Administration (FDA) on the pivotal Phase 3 trial design for VERU-111—its oral, first-in-class, novel alpha and beta tubulin targeting drug candidate being evaluated for the treatment of metastatic castration and novel androgen-blocking agent resistant prostate cancer.  “Input from the FDA was very positive and constructive regarding the VERU-111 pivotal Phase 3 trial design. We received clarity that the indication, ...

Yahoo | July 23, 2020

Read More 'VERU' Stories Here

VERU Price Returns

1-mo -8.99%
3-mo -20.33%
6-mo -27.03%
1-year 25.91%
3-year 32.07%
5-year 38.86%
YTD -27.46%
2019 139.29%
2018 22.81%
2017 25.27%
2016 -37.24%
2015 -63.01%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7799 seconds.